Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

On February 28, 2023, Milestone Pharmaceuticals (Nasdaq: MIST) announced its management team will present at two upcoming investor conferences. The events include the Cowen 43rd Annual Health Care Conference on March 7 at 1:30 p.m. ET and the Oppenheimer 33rd Annual Healthcare Conference on March 14 at 2:40 p.m. ET. Live webcasts of the presentations can be accessed on Milestone's website, with archived replays available for approximately 90 days. Milestone focuses on cardiovascular medicines, with its lead candidate, etripamil, having completed Phase 3 trials for paroxysmal supraventricular tachycardia and a Phase 2 trial for atrial fibrillation.

MONTREAL and CHARLOTTE, N.C., Feb. 28, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will present at the following investor conferences:

• The Cowen 43^rd Annual Health Care Conference on Tuesday, March 7 at 1:30 p.m. ET.
• The Oppenheimer 33^rd Annual Healthcare Conference on Tuesday, March 14 at 2:40 p.m. ET.

A live webcast of each presentation can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com. An archived replay of each presentation will be available on the same website for approximately 90 days following the presentation.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil recently completed its Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and is in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow Milestone on Twitter at @MilestonePharma.

Contact

David Pitts
Argot Partners
212-600-1902
milestone@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-upcoming-investor-conferences-301757236.html

SOURCE Milestone Pharmaceuticals, Inc.

FAQ

What are the dates and times of Milestone Pharmaceuticals' upcoming presentations?

Milestone Pharmaceuticals will present at the Cowen 43rd Annual Health Care Conference on March 7 at 1:30 p.m. ET and the Oppenheimer 33rd Annual Healthcare Conference on March 14 at 2:40 p.m. ET.

How can I access Milestone Pharmaceuticals' presentations online?

Live webcasts of Milestone Pharmaceuticals' presentations can be accessed in the News & Events section of their website, along with archived replays available for approximately 90 days.

What is the focus of Milestone Pharmaceuticals?

Milestone Pharmaceuticals focuses on developing and commercializing innovative cardiovascular medicines.

What is the status of Milestone Pharmaceuticals' lead product candidate?

Milestone's lead product candidate, etripamil, has completed its Phase 3 clinical program for paroxysmal supraventricular tachycardia and is in a Phase 2 trial for atrial fibrillation.

Where does Milestone Pharmaceuticals operate?

Milestone Pharmaceuticals operates in Canada and the United States.